SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

INTRODUCTION: The use of immune-checkpoint inhibitors has drastically improved the management of patients with non-small cell lung cancer (NSCLC), but innate and acquired resistances are hurdles needed to be solved. Immunomodulatory drugs that can reinvigorate the immune cytotoxic activity, in combi...

Descripción completa

Detalles Bibliográficos
Autores principales: Redin, Esther, Garmendia, Irati, Lozano, Teresa, Serrano, Diego, Senent, Yaiza, Redrado, Miriam, Villalba, Maria, De Andrea, Carlos E, Exposito, Francisco, Ajona, Daniel, Ortiz-Espinosa, Sergio, Remirez, Ana, Bertolo, Cristina, Sainz, Cristina, Garcia-Pedrero, Juana, Pio, Ruben, Lasarte, Juan, Agorreta, Jackeline, Montuenga, Luis M, Calvo, Alfonso
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7931761/
https://www.ncbi.nlm.nih.gov/pubmed/33658304
http://dx.doi.org/10.1136/jitc-2020-001496

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7931761/
https://www.ncbi.nlm.nih.gov/pubmed/33658304
http://dx.doi.org/10.1136/jitc-2020-001496

Ejemplares similares